Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
$3.30
+4.6%
$2.62
$1.05
$4.13
$312.41M1.89597,680 shs593,846 shs
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$8.93
+6.4%
$8.04
$5.20
$10.67
$1.13B1.161.40 million shs5.35 million shs
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$34.33
+0.1%
$33.51
$26.47
$41.61
$1.97B0.83633,504 shs569,367 shs
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$2.22
-0.4%
$2.04
$1.04
$3.73
$340.22M1.182.17 million shs827,084 shs
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
$26.98
$26.96
$7.67
$27.06
$2.62B2.171.17 million shs2.26 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
+4.27%+18.10%-10.10%+171.19%+4.60%
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
+6.44%+18.03%+9.57%+20.51%+62.36%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
+0.12%+6.98%-4.24%+17.69%+2.42%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-0.45%+2.54%+4.72%+16.23%-26.97%
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
1.5945 of 5 stars
3.52.00.00.00.00.80.6
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
2.798 of 5 stars
3.51.00.00.02.60.81.9
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
4.8146 of 5 stars
4.51.00.00.03.33.34.4
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
3.9381 of 5 stars
3.50.00.04.23.31.70.6
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
3.00
Buy$7.75135.20% Upside
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
3.00
Buy$11.5028.78% Upside
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
3.00
Buy$51.3349.53% Upside
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
3.00
Buy$5.00125.23% Upside
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ADCT, MYOV, HRTX, HRMY, and AUPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$54.00 ➝ $55.00
7/10/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold$33.00
6/20/2025
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$8.00 ➝ $5.00
6/13/2025
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $10.00
6/9/2025
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
6/2/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$61.00
5/15/2025
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.00
5/15/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$44.00 ➝ $48.00
5/13/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/6/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$49.00 ➝ $49.00
4/28/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $48.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
$70.84M4.61N/AN/A($2.10) per share-1.57
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$235.13M5.13$0.33 per share27.20$2.68 per share3.33
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$714.73M2.76$2.95 per share11.64$11.56 per share2.97
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$148.52M2.28N/AN/A($0.22) per share-10.09
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
$230.97M11.36N/AN/A($5.04) per share-5.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
-$157.85M-$1.45N/AN/AN/A-197.64%N/A-45.57%8/5/2025 (Estimated)
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$5.75M$0.2831.8915.95N/A16.11%14.27%9.93%7/30/2025 (Estimated)
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$145.49M$2.6213.1011.040.5120.53%24.32%15.92%8/5/2025 (Estimated)
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$13.58M-$0.06N/AN/AN/A-5.24%N/A-3.43%8/5/2025 (Estimated)
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
-$205.98M-$1.91N/AN/AN/A-48.47%N/A-39.36%N/A

Latest ADCT, MYOV, HRTX, HRMY, and AUPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$0.18N/AN/AN/A$64.27 millionN/A
8/5/2025Q2 2025
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
-$0.36N/AN/AN/A$17.82 millionN/A
8/5/2025Q2 2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$0.78N/AN/AN/A$204.37 millionN/A
8/5/2025Q2 2025
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$0.01N/AN/AN/A$38.08 millionN/A
5/14/2025Q1 2025
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
-$0.38-$0.36+$0.02-$0.36$17.71 million$23.03 million
5/12/2025Q1 2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$0.08$0.16+$0.08$0.16$61.06 million$62.47 million
5/6/2025Q1 2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$0.59$0.78+$0.19$0.78$184.26 million$184.73 million
5/6/2025Q1 2025
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$0.01$0.01+$0.02$0.01$37.08 million$38.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
N/AN/AN/AN/AN/A
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
N/AN/AN/AN/AN/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
N/AN/AN/AN/AN/A
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
N/A
4.46
4.16
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
0.16
5.93
5.26
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
0.22
3.67
3.63
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
N/A
2.40
1.76
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
N/A
1.57
1.45

Institutional Ownership

CompanyInstitutional Ownership
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
41.10%
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
36.83%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
86.23%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
80.01%
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
30.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
ADC Therapeutics SA stock logo
ADCT
ADC Therapeutics
31099.18 million93.82 millionOptionable
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
300135.10 million118.62 millionOptionable
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
20057.42 million43.87 millionOptionable
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
300152.56 million143.62 millionOptionable
Myovant Sciences Ltd. stock logo
MYOV
Myovant Sciences
40797.24 million95.39 millionNot Optionable

Recent News About These Companies

Myovant Sciences Stock Price History
Myovant Investor Claiming Skadden Conflict Denied Appellate Redo
Myovant Investor Claiming Skadden Conflict Seeks Appellate Redo
Myovant Investor Fails to Revive Skadden Conflict Suit on Appeal
Skadden-Myovant Appeals Court Skeptical of 'Family' Conflict
gears of horus max win
Forendo joins race to develop endometriosis drugs
Probability in the Engineering and Informational Sciences

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADC Therapeutics stock logo

ADC Therapeutics NYSE:ADCT

$3.30 +0.15 (+4.60%)
Closing price 07/10/2025 03:59 PM Eastern
Extended Trading
$3.27 -0.02 (-0.76%)
As of 05:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals NASDAQ:AUPH

$8.93 +0.54 (+6.44%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$8.93 +0.00 (+0.04%)
As of 04:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Harmony Biosciences stock logo

Harmony Biosciences NASDAQ:HRMY

$34.33 +0.04 (+0.12%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$34.33 0.00 (0.00%)
As of 07/10/2025 04:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Heron Therapeutics stock logo

Heron Therapeutics NASDAQ:HRTX

$2.22 -0.01 (-0.45%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$2.22 0.00 (0.00%)
As of 07/10/2025 05:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Myovant Sciences stock logo

Myovant Sciences NYSE:MYOV

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.